Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
Science
; 375(6576): 43-50, 2022 Jan 07.
Article
in English
| MEDLINE | ID: covidwho-1649486
ABSTRACT
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later, with values reported in standardized World Health Organization international units. All markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Vaccine recipients with postvaccination 50% neutralization titers 10, 100, and 1000 had estimated vaccine efficacies of 78% (95% confidence interval, 54 to 89%), 91% (87 to 94%), and 96% (94 to 98%), respectively. These results help define immune marker correlates of protection and may guide approval decisions for messenger RNA (mRNA) COVID-19 vaccines and other COVID-19 vaccines.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Neutralizing
/
SARS-CoV-2
/
COVID-19
/
Vaccine Efficacy
/
2019-nCoV Vaccine mRNA-1273
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
/
Young adult
Language:
English
Journal:
Science
Year:
2022
Document Type:
Article
Affiliation country:
Science.abm3425
Similar
MEDLINE
...
LILACS
LIS